10-K Decoder · All companies

CRISPR Therapeutics AG

CRSP · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$3.51M$37.3M−90.6%
Operating income−$665M−$467M−42.4%
Net income−$582M−$366M−58.8%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 2, 2026

$Q3 2026Year earlierChange
Revenue$12.7M$900K+1,311%
Operating income−$130M−$132M+1.6%
Net income−$111M−$106M−4.7%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was CRISPR's revenue in FY2025?
$3.51M in FY2025 (Fiscal year ended Dec 31, 2025), −90.6% vs $37.3M a year earlier, per its 10-K filed Feb 2026.
Was CRISPR profitable in FY2025?
No: net income was −$582M and operating income −$665M in FY2025.
What was CRISPR's revenue in Q3 2026?
$12.7M (+1,311% vs a year earlier), per its Form 10-Q filed Nov 2, 2026.